Insulin in Type 2 Diabetes – New Options are Transforming Management - Canadian Council On Continuing Education In Pharmacy (CCCEP)

Duration

2 hr

Profession

Pharmacy

# of Credits

2.0

Accreditation

CCCEP

Expiry Date

2020-04-17

This program will update HCPs on the management of T2DM with long-acting basal analogues and therapeutic intensification with combinations of basal insulin and GLP-1 RA.

This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 2 CEUs. CCCEP File Number: 1066-2019-2726-I-P

Ronald Goldenberg, MD, FRCPC, FACE

Esmond Wong, RPh, CDE APA

Susie Jin, RPh, CDE, CPT, BCGP

Upon successful completion of this program, the healthcare professional will be better able to:

  • Determine when to initiate basal insulin therapy in type 2 diabetes
  • Select a basal insulin and titrate the basal insulin dose according to Diabetes Canada 2018 guideline recommendations
  • Discuss the differences between basal insulins
  • Evaluate options for intensification for patients not reaching glycemic targets on basal insulin
  • Describe the potential role of combination basal insulin and GLP-1 receptor agonist therapy and the role of fixed-ratio combinations


Related Courses